Published in Medical Letter on the CDC and FDA, April 12th, 2006
EOquin has previously undergone a number of clinical studies in Europe, including a successful phase 2, marker lesion study, which showed good tolerance and a durable, high complete response rate (67%).
A successful pre-IND and end of phase 2 meeting with the FDA, in January 2006, in which the development strategy, including the phase 3 design and objectives, were discussed, preceded this IND filing. The U.S. clinical study program will initiate...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.